According to WHO, Antimicrobial resistance (AMR) is one of the top global public health and development threats which may increase to 10 million deaths per year by 2050. And the issue is growing – with overuse and misuse, including exposure to long doses of antibiotics exacerbating this issue. To overcome AMR after ocular surgery, recently UKMHRA & EMA approved a new therapy which is the fixed dose combination (FDC) of levofloxacin and dexamethasone eye drops ensures only 7 days treatment period than other combination of topical antibiotic/corticosteroid. That’s why this combination ensures less chances of bacterial resistance. According to a clinical study, it ensures better patients’ tolerability. 7 days combination (Dexamethasone & Levofloxacin) therapy followed by dexamethasone alone for next 7 days, prevents infections and reduces inflammation (95.2%) and pain & discomfort (95%) after ocular surgery. In the meantime, Levofloxacin is a fluoroquinolone antibacterial agent, has wide spectrum of activities against different gram-positive microorganisms (e.g. S. aureus MSSA, S. pyogenes, S. pneumoniae, viridans group Streptococci), aerobic Gram-negative bacteria (e.g. E. coli, H. influenzae, M. catarrhalis, P. aeruginosa community isolates), other organisms (e.g. Chlamydia trachomatis)
FR
DE